Want to see SG:8YY full AI Analyst Report?
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)173.33K
Market Cap
S$60.67M
Enterprise ValueS$74.41
Total Cash (Recent Filing)S$494.00K
Total Debt (Recent Filing)S$2.77M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume349,810
30 Day Avg. Volume173,330
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sharp Revenue ReboundThe 2025 rebound indicates renewed commercialization or demand after a very low 2024 base. If sustained, higher sales can improve operating leverage, broaden customer adoption of the diagnostic portfolio, and provide a foundation for scaling revenue over the next several quarters.
Diagnostics Platform FocusA focus on clinical diagnostics and blood-based testing places the company in healthcare applications where products can support disease detection and monitoring. Successful commercialization could create repeat demand from clinical and laboratory users as adoption expands.
Improving Cash BurnThe much smaller free-cash-flow deficit in 2025 shows a meaningful reduction in cash burn compared with the prior year. Although operations remain cash-consuming, continued improvement could reduce funding pressure and move the business closer to self-financing.
Bears Say
Persistent Operating LossesPersistent operating and net losses show that the revenue rebound has not yet translated into sustainable profitability. Without improved margins and operating leverage, continued losses can consume capital, restrict reinvestment, and leave earnings power dependent on future execution.
Negative Cash GenerationRecurring negative operating and free cash flow indicate that the business has not established a self-funding operating model. Continued cash outflows may require external funding or balance-sheet resources, increasing financial pressure and limiting flexibility for product development.
Thin Equity Cushion And LeverageDebt materially exceeds the current equity base, while earlier periods of negative equity highlight balance-sheet instability. This limited capital cushion reduces resilience if losses persist, constrains strategic investment, and increases reliance on improved operations or additional funding.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$60.67M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Nov 04, 2026 which is in 48 days.
How were Biolidics Ltd.’s earnings last quarter?
Biolidics Ltd. released its earnings results on Aug 12, 2026. The company reported S$0 earnings per share for the quarter.
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Biolidics Ltd. reported an EPS of S$0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a Singapore-based medical technology firm, specializes in precision medicine, focusing on developing diagnostic solutions. Operating across Japan, Hong Kong, Thailand, Malaysia, and the United States, its business is structured into Cancer, Infectious Diseases, and Laboratory Services segments. The company's key innovations include the ClearCell FX1 System, an automated device that, using Streck Cell-free DNA BCT and EDTA tubes, isolates intact and viable circulating tumor cells (CTCs) from small blood samples. It also provides the CTChip FR1 biochip for separating CTCs from leukocytes, alongside offering general laboratory services. Established in 2009, the company was formerly known as Biolidics Limited, adopting its current name in June 2025.
Technical Analysis
Cordlife Group
―
ISEC Healthcare Ltd
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Singapore Institute of Advanced Medicine Holdings Ltd.
―